(Q40775150)

English

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial (English)

1 reference

Europe PubMed Central

23 September 2017

multiple sclerosis

0 references

methylprednisolone

1 reference

based on heuristic

inferred from title

author name string

Emmanuelle Le Page

1

1 reference

Europe PubMed Central

23 September 2017

David Veillard

2

1 reference

Europe PubMed Central

23 September 2017

David A Laplaud

3

1 reference

Europe PubMed Central

23 September 2017

Stéphanie Hamonic

4

1 reference

Europe PubMed Central

23 September 2017

Rasha Wardi

5

1 reference

Europe PubMed Central

23 September 2017

Christine Lebrun

6

1 reference

Europe PubMed Central

23 September 2017

Fabien Zagnoli

7

1 reference

Europe PubMed Central

23 September 2017

Sandrine Wiertlewski

8

1 reference

Europe PubMed Central

23 September 2017

Véronique Deburghgraeve

9

1 reference

Europe PubMed Central

23 September 2017

Marc Coustans

10

1 reference

Europe PubMed Central

23 September 2017

Gilles Edan

11

1 reference

Europe PubMed Central

23 September 2017

COPOUSEP investigators

12

1 reference

Europe PubMed Central

23 September 2017

West Network for Excellence in Neuroscience

13

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

26 June 2015

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

386

1 reference

Europe PubMed Central

23 September 2017

9997

1 reference

Europe PubMed Central

23 September 2017

974-981

1 reference

Europe PubMed Central

23 September 2017

Evidence for a two-stage disability progression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

What we have learned from the Optic Neuritis Treatment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 Tables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

An alternative to the use of two-sided tests in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961137-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)61137-0

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40775150&oldid=1906973783"